Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).
复制标题
DOI：
10.1016/j.jacc.2010.05.050
复制
发表时间：
2010-11-16
影响因子：
24
通讯作者：
Halperin, Jonathan L.
中科院分区：
文献类型：
--
作者：
Elmariah, Sammy;Delaney, Joseph A. C.;O'Brien, Kevin D.;Budoff, Matthew J.;Vogel-Claussen, Jens;Fuster, Valentin;Kronmal, Richard A.;Halperin, Jonathan L.
目的：确定含氮双膦酸盐(NCBP)治疗是否与心血管钙化的患病率相关。心血管钙化与动脉粥样硬化性疾病负担相关。实验数据表明，NCBP可能会限制心血管钙化，这对疾病预防具有重要意义。在动脉粥样硬化多种族研究(MESA)中，对3636名女性使用NCBP与CT检测到的主动脉瓣、主动脉瓣环、二尖瓣环、胸主动脉和冠状动脉钙化(分别为AVC、AVRC、MAC、TAC和CAC)之间的关系进行了评估。分析是按年龄分层的，因为年龄和非农村合作伙伴的使用之间存在显著的交互作用(交互作用p值：AVCp<；0.0001；AVRC p<；0.0001；MACp=0.002；TAC p<；0.0001；CACp=0.046)。在调整了年龄、体重指数、人口统计学、糖尿病、吸烟、血压、胆固醇水平以及他汀类药物、激素替代和肾素-血管紧张素抑制剂治疗后，在≥65岁的女性中，使用NCBP与较低的心血管钙化患病率相关(患病率[95%可信区间]：AVC0.68[0.41，1.13]；AVRC0.65[0.51，0.84]；MAC0.54[0.33，0.93]；TAC0.69[0.54，0.88]；CAC 0.89[0.78，1.02])，而钙化在使用NCBP的2,181名65岁女性中更为普遍(AVC 4.00[2.33，6.89]；AVRC 1.92[1.42，2.61]；MAC 2.35[1.12，4.84]；TAC 2.17[1.49，3.15]；CAC 1.23[0.97，1.57])。在不同MESA队列中的女性中，NCBP与老年受试者心血管钙化发生率降低有关，但在年轻受试者中心血管钙化发生率更高。需要进一步的研究来阐明这些与年龄相关的NCBP效应。
To determine whether nitrogen-containing bisphosphonate (NCBP) therapy is associated with the prevalence of cardiovascular calcification. Cardiovascular calcification correlates with atherosclerotic disease burden. Experimental data suggest that NCBP may limit cardiovascular calcification, which has implications for disease prevention. The relationship of NCBP use to the prevalence of aortic valve, aortic valve ring, mitral annulus, thoracic aorta, and coronary artery calcification (AVC, AVRC, MAC, TAC, and CAC, respectively) detected by computed tomography was assessed in 3,636 women within the Multi-Ethnic Study of Atherosclerosis (MESA) using regression modeling. Analyses were age-stratified because of a significant interaction between age and NCBP use (interaction p-values: AVC p<0.0001; AVRC p<0.0001; MAC p=0.002; TAC p<0.0001; CAC p=0.046). After adjusting for age, body mass index, demographics, diabetes, smoking, blood pressure, cholesterol levels, and statin, hormone replacement, and renin-angiotensin inhibitor therapy, NCBP use was associated with a lower prevalence of cardiovascular calcification in women ≥65 years old (prevalence ratio [95% confidence interval]: AVC 0.68 [0.41, 1.13]; AVRC 0.65 [0.51, 0.84]; MAC 0.54 [0.33, 0.93]; TAC 0.69 [0.54, 0.88]; CAC 0.89 [0.78, 1.02]), whereas calcification was more prevalent in NCBP users among the 2,181 women <65 years old (AVC 4.00 [2.33, 6.89]; AVRC 1.92 [1.42, 2.61]; MAC 2.35 [1.12, 4.84]; TAC 2.17 [1.49, 3.15]; CAC 1.23 [0.97, 1.57]). Among women in the diverse MESA cohort, NCBPs were associated with decreased prevalence of cardiovascular calcification in older subjects, but more prevalent cardiovascular calcification in younger ones. Further study is warranted to clarify these age-dependent NCBP effects.
登录
查看更多内容
影响因子：
158.5
作者：
Lyles, Kenneth W.;Colon-Emeric, Cathleen S.;Boonen, Steven
通讯作者：
Boonen, Steven
影响因子：
24
作者：
Goldbarg, Seth H.;Elmariah, Sammy;Fuster, Valentin
通讯作者：
Fuster, Valentin
影响因子：
6.2
作者：
Luckman, SP;Hughes, DE;Rogers, MJ
通讯作者：
Rogers, MJ
DOI：
10.1016/0735-1097(90)90282-t
发表时间：
1990-03-15
影响因子：
24
作者：
AGATSTON, AS;JANOWITZ, WR;DETRANO, R
通讯作者：
DETRANO, R
影响因子：
3.2
作者：
Ariyoshi, Tsuneo;Eishi, Kiyoyuki;Odate, Tomohiro
通讯作者：
Odate, Tomohiro